IL2 and neoplasm: Advances in viral transduction and electroporation now allow for detailed characterization of genetically modified NK cells and provide a better understanding of how these cells can be used clinically to optimize their capacity to induce tumor regression in vivo through approaches such as improving NK-cell persistence via autocrine IL-2 and IL-15 stimulation, enhancing tumor targeting by silencing inhibitory NK-cell receptors such as NKG2A, and redirecting tumor killing via chimeric antigen receptors [260].